---
figid: PMC4661858__ijms-16-26000-g003
figtitle: Inhibitors developed against EZH2
organisms:
- Nicotiana tabacum
- Clarkia concinna
- Homo sapiens
- Mus musculus
- Mycobacterium tuberculosis variant bovis BCG
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC4661858
filename: ijms-16-26000-g003.jpg
figlink: /pmc/articles/PMC4661858/figure/ijms-16-26000-f003/
number: F3
caption: 'Inhibitors developed against EZH2. The five types of inhibitors are indicated:
  “S-adenosyl-l-homocysteine hydrolase inhibitors”, “S-adenosyl-l-methionine competitive
  inhibitors”, “S-adenosyl-l-homocysteine-EZH2 peptides as disruptors of the contact
  between EZH2 and EED”, “Degradation by ubiquitin proteasome pathway”, and “Downregulation
  mediated by the increased expression of miRNAs target of EZH2”. EZH2: Enhancer of
  zeste homolog 2. SUZ12: Zinc finger protein suppressor of zeste 12. EED:WD40 Repeat
  protein embryonic ectoderm development. SET: Su(var)3-9E Enhancer of zeste and Trithorax
  RbAp48: Retinoblastoma-binding protein p48. AEBP2: Adipocyte Enhancer-Binding Protein
  2. DZNep: 3-dezaneplanocin-A Me: methylation. Ub: ubiquitination Mir101: miRNA-101.
  Arrow blue: activation of different pathways Arrow red: inhibition of different
  molecules. Light blue cylinders are histones, and with red ribbons are DNA.'
papertitle: EZH2 in Bladder Cancer, a Promising Therapeutic Target.
reftext: Mónica Martínez-Fernández, et al. Int J Mol Sci. 2015 Nov;16(11):27107-27132.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9495883
figid_alias: PMC4661858__F3
figtype: Figure
redirect_from: /figures/PMC4661858__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4661858__ijms-16-26000-g003.html
  '@type': Dataset
  description: 'Inhibitors developed against EZH2. The five types of inhibitors are
    indicated: “S-adenosyl-l-homocysteine hydrolase inhibitors”, “S-adenosyl-l-methionine
    competitive inhibitors”, “S-adenosyl-l-homocysteine-EZH2 peptides as disruptors
    of the contact between EZH2 and EED”, “Degradation by ubiquitin proteasome pathway”,
    and “Downregulation mediated by the increased expression of miRNAs target of EZH2”.
    EZH2: Enhancer of zeste homolog 2. SUZ12: Zinc finger protein suppressor of zeste
    12. EED:WD40 Repeat protein embryonic ectoderm development. SET: Su(var)3-9E Enhancer
    of zeste and Trithorax RbAp48: Retinoblastoma-binding protein p48. AEBP2: Adipocyte
    Enhancer-Binding Protein 2. DZNep: 3-dezaneplanocin-A Me: methylation. Ub: ubiquitination
    Mir101: miRNA-101. Arrow blue: activation of different pathways Arrow red: inhibition
    of different molecules. Light blue cylinders are histones, and with red ribbons
    are DNA.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Ezh2
  - Aebp2
  - Rbbp4
  - Eed
  - Set
  - Mir101a
  - Snhg15
  - Acsm3
  - El1
  - D9Mgc46e
  - Pdpn
  - EZH2
  - AEBP2
  - RBBP4
  - EED
  - SET
  - ACSM3
  - EPB41
  - CG11700
  - E(z)
  - jing
  - Caf1-55
  - I-2
  - sam
  - qkr54B
  - sls
  - Sam-S
  - sah
  - Me
  - EPZ6438
  - Gambogic Acid
  - Methyl Jasmonate
  - Adenosine
  - methionine
---
